Wirkungsmechanismus von oral applizierten proteolytischen Enzymen – Mechanistische und therapeutische Aspekte

Proteasen regulieren den intrazellulären und extrazellulären Abbau von körpereigenen und exogenen Eiweißen. Proteasen modulieren fundamentale biologische Prozesse wie z. B. Blutgerinnung und Fibrinolyse, Komplementaktivierung, Antigenaufnahme und -präsentation, Aktivierung von körpereigenen antimikrobiellen Peptiden und Amyloidbildung. Die Aktivität vieler Proteasen unterliegt einer strengen Regulation durch Antiproteasen (Proteaseinhibitoren). Ein bedeutender Proteaseinhibitor ist das alpha2-Makroglobulin (A2M) des menschlichen Blutes. Auf Grund seines Hemmmechanismus kann es die Wirkung von Proteasen verstärken und diversifizieren.

Literatur

• 1 Binder R J, Han D K, Srivastava P K. CD91: a receptor for heat shock protein gp96.  Nat Immunol. 2000;  1 (2) 151-5
• 2 Birkenmeier G, Kämpfer I, Kratzsch J, Schellenberger W. Human leptin forms complexes with alpha 2-macroglobulin which are recognized by the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein.  Eur J Endocrinol. 1998;  139 (2) 224-30
• 3 Birkenmeier G, Müller R, Huse K, Forberg J, Gläser C, Hedrich H, Nicklisch S, Reichenbach A. Human alpha2-macroglobulin: genotype-phenotype relation.  Exp Neurol. 2003;  184 (1) 153-61
• 4 Birkenmeier G, Nicklisch S, Pockelt C, Mossie A, Steger V, Gläser C, Hauschildt S, Usbeck E, Huse K, Sack U, Bauer M, Schäfer A. Polymyxin B-conjugated alpha 2-macroglobulin as an adjunctive therapy to sepsis: Modes of action and impact on lethality.  J Pharmacol Exp Ther. 2006;  318 (2) 762-71
• 5 Birkenmeier G, Stigbrand T. Production of conformation-specific monoclonal antibodies against alpha 2 macroglobulin and their use for quantitation of total and transformed alpha 2 macroglobulin in human blood.  J Immunol Methods. 1993;  162 (1) 59-67
• 6 Birkenmeier G. Targetting the proteinase inhibitor and immune modulatory function of human a2-macroglobulin.  Mod Asp Immunbiol. 2001;  2 32-36
• 7 Bock U, Kolac C, Borchard G, Koch K, Fuchs R, Streichhan P, Lehr C M. Transport of proteolytic enzymes across Caco-2 cell monolayers.  Pharm Res. 1998;  15 (9) 1393-400
• 8 Cardillo M R, Petrangeli E, Perracchio L, Salvatori L, Ravenna L, Di Silverio F. Transforming growth factor-beta expression in prostate neoplasia.  Anal Quant Cytol Histol. 2000;  22 (1) 1-10
• 9 Castell J V, Friedrich G, Kuhn C S, Poppe G E. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake.  Am J Physiol. 1997;  273 (1 Pt 1) G139-46
• 10 Chu C T, Howard G C, Misra U K, Pizzo S V. Alpha 2-macroglobulin: a sensor for proteolysis.  Ann N Y Acad Sci. 1994;  737 291-307
• 11 Deane R, Zlokovic B V. Role of the blood-brain barrier in the pathogenesis of Alzheimer’s disease.  Curr Alzheimer Res. 2007;  4 (2) 191-7
• 12 Desser L, Holomanova D, Zavadova E, Pavelka K, Mohr T, Herbacek I. Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood.  Cancer Chemother Pharmacol. 2001;  47 Suppl S10-5
• 13 Lauer D, Müller R, Cott C, Otto A, Naumann M, Birkenmeier G. Modulation of growth factor binding properties of alpha2-macroglobulin by enzyme therapy.  Cancer Chemother Pharmacol. 2001;  47 Suppl S4-9
• 14 Lauer D, Reichenbach A, Birkenmeier G. Alpha 2-macroglobulin-mediated degradation of amyloid beta 1 – 42: a mechanism to enhance amyloid beta catabolism.  Exp Neurol. 2001;  167 (2) 385-92
• 15 Li M O, Flavell R A. TGF-beta: a master of all T cell trades.  Cell. 2008;  134 (3) 392-404
• 16 Nalivaeva N N, Fisk L R, Belyaev N D, Turner A J. Amyloid-degrading enzymes as therapeutic targets in Alzheimer’s disease.  Curr Alzheimer Res. 2008;  5 (2) 212-24
• 17 Paczek L, Michalska W, Bartlomiejczyk I. Trypsin, elastase, plasmin and MMP-9 activity in the serum during the human ageing process.  Age Ageing. 2008;  37 (3) 318-23
• 18 Sinnreich O, Kratzsch J, Reichenbach A, Gläser C, Huse K, Birkenmeier G. Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters.  Prostate. 2004;  61 (3) 201-8
• 19 Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation.  J Biol Chem. 1989;  264 (20) 11 539-42
• 20 Waldron E, Heilig C, Schweitzer A, Nadella N, Jaeger S, Martin A M, Weggen S, Brix K, Pietrzik C U. LRP1 modulates APP trafficking along early compartments of the secretory pathway.  Neurobiol Dis. 2008;  31 (2) 188-97
• 21 Webb D J, Gonias S L. A modified human alpha 2-macroglobulin derivative that binds tumor necrosis factor-alpha and interleukin-1 beta with high affinity in vitro and reverses lipopolysaccharide toxicity in vivo in mice.  Lab Invest. 1998;  78 (8) 939-48
• 22 Wu S M, Patel D D, Pizzo S V. Oxidized alpha2-macroglobulin (alpha2M) differentially regulates receptor binding by cytokines/growth factors: implications for tissue injury and repair mechanisms in inflammation.  J Immunol. 1998;  161 (8) 4356-65